BioSpace News Archive

Tenax Therapeutics, Inc. announced the appointment of Javed Butler, M.D., M.P.H, M.B.A., to the Company’s PH-HFpEF Scientific Advisory Board.

Scilex Holding Company today announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455 (the ”Patent”).

Sana Biotechnology, Inc. and Uppsala University Hospital in Sweden today announced the Swedish Medical Products Agency has authorized Uppsala University’s Clinical Trial Application (CTA) to initiate an investigator-sponsored, first-in-human study of UP421, an allogeneic, primary islet cell therapy engineered with Sana’s hypoimmune (HIP) technology, in patients with type 1 diabetes.

AffyImmune Therapeutics, Inc. was awarded the first-ever Best Oncology R&D Advance at the 2023 Scrip Awards.

Taiho Oncology Inc. and Astex Pharmaceuticals, Inc. announced today details of studies to be presented at the 65th American Society of Hematology (ASH) Annual Meeting, to be held Dec. 9-12, 2023, in San Diego.

Phase Genomics, Inc., a global innovator for industry-leading genomic solutions, today announced the presentation of new data from the proximity ligation sequencing-based OncoTerra cytogenomics platform on the leading-edge AVITI next-generation sequencing system.

Today BIOVECTRA celebrates the completion of its $90 million plus biologics expansion at the company’s new state-of-the-art Biomanufacturing Centre with project partners the Government of Canada and Government of Prince Edward Island.

VolitionRx Limited, a multi-national epigenetics company, is presenting at the 5th Annual Congress of Liquid Biopsy being held in Madrid, Spain.

The global process chromatography market size was valued at USD 12.5 billion in 2022 and is projected to surpass around USD 27.87 billion by 2032, expanding at a healthy CAGR of 8.4% from 2023 to 2032.

Owl Therapeutics, a wholly-owned subsidiary of Gryphon Bio, today announced a global licensing and collaboration agreement with Abliva AB of Lund, Sweden, to advance Abliva’s NeuroSTAT® (OWL-1410) for the prevention and treatment of moderate to severe traumatic brain injury (TBI).